Q3 FY21 results and investor call takeaways - Dr Reddys - YES Securities

- With cost levers having played out over FY19-21 coupled with no significant rise in dollar R&D budget, reckon margin support would have to come from US revenue boost

- A diversified US business (compared to top heavy of Lupin) and less risky pathway to growth (compared to branded play in Sun) makes DRRD a preferred bet in large cap pharma

- Impairment hit leads to necessary cut in FY21 EPS; roll over to FY23 along with Rs300/share Revlimid NPV results in 16% upside. ADD stays

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4598.65 as compared to the previous close of Rs. 4876.35. The total number of shares traded during the day was 93752 in over 13165 trades.

The stock hit an intraday high of Rs. 4916.95 and intraday low of 4550. The net turnover during the day was Rs. 442154658.

Source : Equity Bulls

Keywords